This page is part of the FHIR Specification (v4.5.0: R5 Preview #3). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions
. Page versions: R5 R4B
| Biomedical Research and Regulation Work Group | Maturity Level: N/A | Standards Status: Informative | Compartments: Not linked to any defined compartments |
Raw JSON (canonical form + also see JSON Format Specification)
Simple version of a product (more than basic), only using MedicinalProductDefinition, Ingredient and RegulatedAuthorization
{
"resourceType": "MedicinalProductDefinition",
"id": "equilidem-with-ing-and-auth",
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative</b></p><p><b>id</b>: equilidem-with-ing-and-auth</p><p><b>identifier</b>: id: Equilidem25</p><p><b>combinedPharmaceuticalDoseForm</b>: <span>tablet</span></p><p><b>indication</b>: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.</p><p><b>legalStatusOfSupply</b>: <span>Prescription only medicine</span></p><p><b>classification</b>: <span>B01A</span></p><p><b>ingredient</b>: </p><ul><li><a> </a></li><li><a> </a></li></ul><blockquote><p><b>id</b>: EquilidoniumPhosphate</p><p><b>role</b>: <span>active</span></p><blockquote><p><b>substance</b></p><p><b>code</b>: <span>Equilidonium Phosphate</span></p><h3>Strengths</h3><table><tr><td>-</td><td><b>Presentation</b></td></tr><tr><td>*</td><td>22 ml/1 tablet</td></tr></table></blockquote></blockquote><blockquote><p><b>id</b>: CalciumCarbonate</p><p><b>role</b>: <span>excipient</span></p><blockquote><p><b>substance</b></p><p><b>code</b>: <span>Calcium Carbonate</span></p><h3>Strengths</h3><table><tr><td>-</td><td><b>Presentation</b></td></tr><tr><td>*</td><td>3 ml/1 tablet</td></tr></table></blockquote></blockquote><h3>Names</h3><table><tr><td>-</td><td><b>ProductName</b></td></tr><tr><td>*</td><td>Equilidem 2.5 mg film-coated tablets</td></tr></table><h3>CrossReferences</h3><table><tr><td>-</td><td><b>Product</b></td></tr><tr><td>*</td><td/></tr></table><h3>ManufacturingBusinessOperations</h3><table><tr><td>-</td><td><b>Manufacturer</b></td></tr><tr><td>*</td><td><span>EquiliDrugCo Processing Inc.</span></td></tr></table></div>"
},
"contained": [
{
"resourceType": "Ingredient",
"id": "EquilidoniumPhosphate",
"role": {
"coding": [
{
"system": "http://example.org.uk/fhir/ingredientType",
"code": "active"
}
]
},
"substance": {
"codeCodeableConcept": {
"coding": [
{
"system": "http://example.org.uk/fhir/substances",
"code": "123456",
"display": "Equilidonium Phosphate"
}
]
},
"strength": [
{
"presentation": {
"numerator": {
"value": 22,
"unit": "ml"
},
"denominator": {
"value": 1,
"unit": "tablet"
}
}
}
]
}
},
{
"resourceType": "Ingredient",
"id": "CalciumCarbonate",
"role": {
"coding": [
{
"system": "http://example.org.uk/fhir/ingredientType",
"code": "excipient"
}
]
},
"substance": {
"codeCodeableConcept": {
"coding": [
{
"system": "http://example.org.uk/fhir/substances",
"code": "456789",
"display": "Calcium Carbonate"
}
]
},
"strength": [
{
"presentation": {
"numerator": {
"value": 3,
"unit": "ml"
},
"denominator": {
"value": 1,
"unit": "tablet"
}
}
}
]
}
}
],
"identifier": [
{
"system": "http://example.org.uk/fhir/product",
"value": "Equilidem25"
}
],
"combinedPharmaceuticalDoseForm": {
"coding": [
{
"system": "http://example.org.uk/fhir/dosefom",
"code": "tablet"
}
]
},
"indication": "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.",
"legalStatusOfSupply": {
"coding": [
{
"system": "http://example.org.uk/fhir/legalstatusofsupply",
"code": "POM",
"display": "Prescription only medicine"
}
]
},
"classification": [
{
"coding": [
{
"system": "http://www.whocc.no/atc/example",
"code": "B01A"
}
]
}
],
"ingredient": [
{
"reference": "#EquilidoniumPhosphate"
},
{
"reference": "#CalciumCarbonate"
}
],
"name": [
{
"productName": "Equilidem 2.5 mg film-coated tablets"
}
],
"crossReference": [
{
"product": {
"reference": {
"reference": "MedicinalProductDefinition/genericEquilidonium"
}
}
}
],
"manufacturingBusinessOperation": [
{
"manufacturer": [
{
"display": "EquiliDrugCo Processing Inc."
}
]
}
]
}
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.